Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHUKRA PHARMA vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SHUKRA PHARMA   MYLAN
EQUITY SHARE DATA
    SHUKRA PHARMA
Mar-23
MYLAN
Dec-18
SHUKRA PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs893,965-   
Low Rs112,182-   
Sales per share (Unadj.) Rs53.71,824.3-  
Earnings per share (Unadj.) Rs4.049.5-  
Cash flow per share (Unadj.) Rs5.7391.1-  
Dividends per share (Unadj.) Rs0.500-  
Avg Dividend yield %1.00-  
Book value per share (Unadj.) Rs23.11,973.5-  
Shares outstanding (eoy) m10.96514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.91.7 55.2%   
Avg P/E ratio x12.462.0 20.0%  
P/CF ratio (eoy) x8.87.9 111.5%  
Price / Book Value ratio x2.21.6 138.9%  
Dividend payout %12.40-   
Avg Mkt Cap Rs m5471,581,265 0.0%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m440-   
Avg. sales/employee Rs Th026,817.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0728.2-  
INCOME DATA
Net Sales Rs m588938,595 0.1%  
Other income Rs m120-   
Total revenues Rs m600938,595 0.1%   
Gross profit Rs m54242,874 0.0%  
Depreciation Rs m18175,742 0.0%   
Interest Rs m345,143 0.0%   
Profit before tax Rs m4421,989 0.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m0-3,498 -0.0%   
Profit after tax Rs m4425,487 0.2%  
Gross profit margin %9.125.9 35.2%  
Effective tax rate %0.8-15.9 -5.0%   
Net profit margin %7.52.7 275.8%  
BALANCE SHEET DATA
Current assets Rs m531524,111 0.1%   
Current liabilities Rs m425382,135 0.1%   
Net working cap to sales %18.015.1 118.7%  
Current ratio x1.21.4 91.0%  
Inventory Days Days084 0.0%  
Debtors Days Days1,87393 2,006.9%  
Net fixed assets Rs m219182,072 0.1%   
Share capital Rs m39500 7.8%   
"Free" reserves Rs m2140-   
Net worth Rs m2531,015,388 0.0%   
Long term debt Rs m381,095,930 0.0%   
Total assets Rs m7502,723,666 0.0%  
Interest coverage x16.81.5 1,130.3%   
Debt to equity ratio x0.11.1 13.8%  
Sales to assets ratio x0.80.3 227.7%   
Return on assets %6.32.6 241.1%  
Return on equity %17.42.5 694.0%  
Return on capital %16.23.2 511.0%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m32195,040 0.0%  
From Investments Rs m-44-100,814 0.0%  
From Financial Activity Rs m49-90,861 -0.1%  
Net Cashflow Rs m371,616 2.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 83.29 Rs / USD

Compare SHUKRA PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare SHUKRA PHARMA With: LINK PHARMA  GANGA PHARMACEUTICALS  BIOCON   IND. SWIFT  ORTIN LABS   



Today's Market

Gift Nifty Down 65 Points | Axis Bank Q4 Results | Why Telecom Stocks are Falling | Top Buzzing Stocks Today Gift Nifty Down 65 Points | Axis Bank Q4 Results | Why Telecom Stocks are Falling | Top Buzzing Stocks Today(Pre-Open)

Indian share markets continued the momentum as the session progressed and ended the higher.